[
  {
    "info": {
      "NCT": "NCT03947385",
      "Protocol_No": "IDE196-001",
      "jit": "Caris",
      "trial_name": "IDEAYA BioSciences IDE196-001"
    },
    "disease": {
      "summary": "Solid Tumors, Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer",
      "details": [
        {
          "code": "Uveal Melanoma (UM)",
          "selection": "include"
        },
        {
          "code": "Cutaneous Melanoma (SKCM)",
          "selection": "include"
        },
        {
          "code": "Colorectal Adenocarcinoma (COADREAD)",
          "selection": "include"
        },
        {
          "code": "Solid Tumors",
          "selection": "include"
        }
      ]
    },
    "query": {
      "nct": "NCT03947385",
      "title": "Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions",
      "current_status": "Recruiting",
      "status_verif_date": "December 2021",
      "last_update_date": "May 10, 2022",
      "trial_hold_status": "open",
      "sponsor": "IDEAYA Biosciences",
      "brief_summary": "This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors.\n\nPhase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study.\n\nPhase 1 Tablet and Food Effect Pharmacokinetic (PK) Substudy will assess the PK profile of IDE196 tablet and evaluate the effects of food on the PK profile of IDE196 tablet\n\nPhase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study.\n\nPhase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study.",
      "conditions": "Metastatic Uveal Melanoma | Cutaneous Melanoma | Colorectal Cancer | Other Solid Tumors",
      "type": "Interventional",
      "phase": "Phase 1 | Phase 2",
      "arm": [
        {
          "ArmID": "1",
          "cohortlabel": "Dose Escalation Monotherapy",
          "drug": "IDE196 | NA",
          "arm_type": "Experimental",
          "line_of_therapy": "Not available",
          "arm_hold_status": "open",
          "biomarker": [
            {}
          ]
        },
        {
          "ArmID": "2",
          "cohortlabel": "Dose Expansion Monotherapy",
          "drug": "IDE196 | NA",
          "arm_type": "Experimental",
          "line_of_therapy": "Not available",
          "arm_hold_status": "open",
          "biomarker": [
            {
              "cohort": "Dose Expansion Monotherapy",
              "Gene": "GNAQ",
              "Gene2": "Not available",
              "Type": "Mutation",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available",
              "summary": "GNAQ Mutation  "
            },
            {
              "cohort": "Dose Expansion Monotherapy",
              "Gene": "GNA11",
              "Gene2": "Not available",
              "Type": "Mutation",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available",
              "summary": "GNA11 Mutation  "
            },
            {
              "cohort": "Dose Expansion Monotherapy",
              "Gene": "PRKC",
              "Gene2": "Not available",
              "Type": "Fusion",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available"
            }
          ]
        },
        {
          "ArmID": "3",
          "cohortlabel": "Dose Escalation Binimetinib Combination",
          "drug": "IDE196 | Binimetinib",
          "arm_type": "Experimental",
          "line_of_therapy": "Not available",
          "arm_hold_status": "open",
          "biomarker": [
            {}
          ]
        },
        {
          "ArmID": "4",
          "cohortlabel": "Dose Expansion Binimetinib Combination",
          "drug": "IDE196 | Binimetinib",
          "arm_type": "Experimental",
          "line_of_therapy": "Not available",
          "arm_hold_status": "open",
          "biomarker": [
            {
              "cohort": "Dose Expansion Binimetinib Combination",
              "Gene": "GNAQ",
              "Gene2": "Not available",
              "Type": "Mutation",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available",
              "summary": "GNAQ Mutation  "
            },
            {
              "cohort": "Dose Expansion Binimetinib Combination",
              "Gene": "GNA11",
              "Gene2": "Not available",
              "Type": "Mutation",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available",
              "summary": "GNA11 Mutation  "
            },
            {
              "cohort": "Dose Expansion Binimetinib Combination",
              "Gene": "PRKC",
              "Gene2": "Not available",
              "Type": "Fusion",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available"
            }
          ]
        },
        {
          "ArmID": "5",
          "cohortlabel": "Dose Escalation Crizotinib Combination",
          "drug": "IDE196 | Crizotinib",
          "arm_type": "Experimental",
          "line_of_therapy": "Not available",
          "arm_hold_status": "open",
          "biomarker": [
            {}
          ]
        },
        {
          "ArmID": "6",
          "cohortlabel": "Dose Expansion Crizotinib Combination",
          "drug": "IDE196 | Crizotinib",
          "arm_type": "Experimental",
          "line_of_therapy": "Not available",
          "arm_hold_status": "open",
          "biomarker": [
            {
              "cohort": "Dose Expansion Crizotinib Combination",
              "Gene": "GNAQ",
              "Gene2": "Not available",
              "Type": "Mutation",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available",
              "summary": "GNAQ Mutation  "
            },
            {
              "cohort": "Dose Expansion Crizotinib Combination",
              "Gene": "GNA11",
              "Gene2": "Not available",
              "Type": "Mutation",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available",
              "summary": "GNA11 Mutation  "
            },
            {
              "cohort": "Dose Expansion Crizotinib Combination",
              "Gene": "PRKC",
              "Gene2": "Not available",
              "Type": "Fusion",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available"
            }
          ]
        },
        {
          "ArmID": "7",
          "cohortlabel": "Tablet PK Substudy",
          "drug": "IDE196 | NA",
          "arm_type": "Experimental",
          "line_of_therapy": "Not available",
          "arm_hold_status": "open",
          "biomarker": [
            {}
          ]
        }
      ],
      "docs": "Q:/MCK/MOA/Precision Oncology/JIT Trials/CarisPharmatechStudyList_2022-07-12.pdf",
      "min_age": "18 Years",
      "gender": "All",
      "link": "<a href=\"https://clinicaltrials.gov/ct2/show/NCT03947385\" target=\"_blank\">NCT03947385<\/a>"
    }
  }
]
